Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Aristotle Core Equity Fund 2024 Q2 Investor Letter | Buyside Digest

Back to Fund Profile (Aristotle Core Equity Fund)

Primary Source Intelligence • Q2 2024 Letter Analysis

Aristotle Core Equity Fund Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Aristotle Core Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

Annualized+13.88%

Digest Analysis

Quick Take

"Aristotle Core Equity outperformed in Q2 2024 driven by AI beneficiaries NVIDIA and Alphabet. The fund added positions in Amphenol, Boston Scientific, and Microchip Technology to capitalize on data center infrastructure, healthcare recovery, and industrial IoT trends."

Executive Summary

The Aristotle Core Equity Fund delivered strong performance in Q2 2024, returning 5.45% and outperforming the S&P 500's 4.28% return. The fund's outperformance was driven primarily by security selection in Information Technology and Health Care. Key contributors included NVIDIA, which benefited from accelerating demand for GPU semiconductors from hyperscalers and enterprises driving AI compute applications, and Alphabet, which posted strong earnings across all businesses while maintaining search market leadership despite GenAI competition. The fund made strategic additions including Amphenol, positioned to benefit from AI-enabled data center infrastructure spending, Boston Scientific, capitalizing on post-COVID healthcare utilization recovery and aging demographics, and Microchip Technology, expected to benefit from industrial and IoT demand recovery. Detractors included Darling Ingredients due to below-consensus EBITDA guidance and Norfolk Southern facing volume weakness and activist investor pressure. The fund sold Abbott Laboratories, Accenture, and Teleflex due to valuation concerns and growth headwinds. Looking forward, the managers remain focused on companies with secular tailwinds while acknowledging elevated market valuations and potential volatility.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

68%

CautiousHigh

Moderate (68%)

The fund demonstrates moderate-high conviction through concentrated holdings with the top 10 positions representing significant portfolio weight, detailed thesis explanations for new additions, and specific reasoning for sales. The manager provides clear rationale for position changes and names specific holdings with sizing context, though the diversified nature across multiple sectors prevents a higher score.

Growth Outlook

25%

BearishBullish

Bearish (25%)

The manager acknowledges positive earnings growth and potential rate cuts but expresses caution about elevated valuations, slowing economic activity, geopolitical uncertainty, and potential for higher volatility. The outlook is mildly positive but tempered by multiple risk factors.

Risk Appetite

40%

DefensiveAggressive

Defensive (40%)

The fund actively added three new positions while selling three others, indicating selective risk-taking. The positioning shows willingness to deploy capital in AI and healthcare themes while trimming positions with valuation or growth concerns, suggesting a moderately positive risk appetite.

Capital Deployment

0%

De-riskingDeploying

De-risking (0%)

The fund engaged in capital rotation, selling three positions (Abbott, Accenture, Teleflex) and adding three new positions (Amphenol, Boston Scientific, Microchip Technology). This represents reallocation rather than net deployment or de-risking, as proceeds from sales funded new purchases with no indication of cash level changes.

Forward Guidance

30%

CautiousExpansionary

Cautious (30%)

The manager states they will continue focusing on companies with secular tailwinds, indicating selective deployment bias. However, the acknowledgment of elevated valuations and potential volatility suggests a measured approach to future positioning.

Language Signal

15%

BearishBullish

Bearish (15%)

The letter contains more risk-oriented language including elevated valuations, slowing economic activity, geopolitical uncertainty, and potential volatility, balanced against some positive language about earnings growth and secular tailwinds. The net balance tilts slightly toward caution.

Perceived Risk

65%

Low RiskElevated

Elevated Risk (65%)

The manager identifies multiple specific risks including elevated equity valuations particularly in AI-focused companies, slowing economic activity with manufacturing contraction, geopolitical uncertainty, and potential for higher market volatility. These risks are discussed with meaningful detail and concern, indicating above-average risk perception.

Opportunity Density

60%

ScarceAbundant

Selective (60%)

The manager sees selective opportunities in defined areas, particularly around AI infrastructure, healthcare recovery, and industrial IoT themes. The addition of three new positions suggests available opportunities, but the emphasis on selectivity and focus on specific secular tailwinds indicates a moderately selective environment rather than broad opportunity abundance.

Time Horizon

70%

Short-TermLong-Term

Decade+ (70%)

The fund demonstrates a multi-year investment horizon, particularly evident in the Boston Scientific investment based on a long-range plan through 2026 and Amphenol positioned for multi-year AI infrastructure buildout. The focus on secular tailwinds and product-driven cycles suggests a 2-4 year thesis timeframe, though no explicit permanent capital structure is mentioned.